Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00080
|
|||||
| Drug Name |
Riociguat
|
|||||
| Synonyms |
625115-55-1; Adempas; BAY 63-2521; CHEBI:76018; Methyl (4,6-diamino-2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-5-yl)(methyl)carbamate; Methyl N-(4,6-diamino-2-{1-((2-fluorophenyl)methyl)-1H-pyrazolo(3,4-b)pyridin-3-yl}pyrimidin-5-yl)-N-methylcarbamate; N-[4,6-Diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methylcarbamic acid methyl ester; RU3FE2Y4XI; Riociguat; Riociguat (BAY 63-2521); UNII-RU3FE2Y4XI; riociguatum
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Pulmonary arterial hypertension [ICD11: BB01.0] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C20H19FN8O2
|
|||||
| Canonical SMILES |
CN(C1=C(N=C(N=C1N)C2=NN(C3=C2C=CC=N3)CC4=CC=CC=C4F)N)C(=O)OC
|
|||||
| InChI |
InChI=1S/C20H19FN8O2/c1-28(20(30)31-2)15-16(22)25-18(26-17(15)23)14-12-7-5-9-24-19(12)29(27-14)10-11-6-3-4-8-13(11)21/h3-9H,10H2,1-2H3,(H4,22,23,25,26)
|
|||||
| InChIKey |
WXXSNCNJFUAIDG-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 625115-55-1
|
|||||
| Pharmaceutical Properties | Molecular Weight | 422.4 | Topological Polar Surface Area | 138 | ||
| Heavy Atom Count | 31 | Rotatable Bond Count | 5 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 9 | |||
| XLogP |
1.6
|
|||||
| PubChem CID | ||||||
| PubChem SID |
124490312
, 124759703
, 126644888
, 126680174
, 135263495
, 136946407
, 137126926
, 139526076
, 144115685
, 152040137
, 152255058
, 152258603
, 160647437
, 160682218
, 16393220
, 164042214
, 164347391
, 170501515
, 172919534
, 178101941
, 185997052
, 198980755
, 198993771
, 211536089
, 223399697
, 223676750
, 224002579
, 226595445
, 23472114
, 242826663
, 249737057
, 249821754
, 251971381
, 252155071
, 252211224
, 252216203
, 252316121
, 252438349
, 252553251
, 42384129
, 80225677
, 87550988
|
|||||
| ChEBI ID |
CHEBI:76018
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [3] | ||
| References | ||||||
| 1 | Riociguat was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01913) | |||||
| 3 | Pharmacokinetic interaction profile of riociguat, a new soluble guanylate cyclase stimulator, initro. Pulm Pharmacol Ther. 2014 Aug;28(2):130-7. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.